December 28th, 2011
No Mortality Benefit of Low-Molecular-Weight Heparin in Acutely Ill Patients
Larry Husten, PHD
Although venous thromboembolism (VTE) is a serious problem for acutely ill patients in the hospital, a new study published in the New England Journal of Medicine failed to find any improvement in mortality associated with thromboprophylaxis. Ajay Kakkar and the LIFENOX investigators randomized 8307 acutely ill patients to receive enoxaparin or placebo for 10 days. All patients wore elastic […]
July 23rd, 2010
FDA Approves Generic Enoxaparin
Larry Husten, PHD
The FDA announced on Friday that it had approved the first generic enoxaparin sodium injection for multiple indications including prevention of deep vein thrombosis (DVT). The action represents the FDA’s first generic approval of a low molecular weight heparin. The original version of enoxaparin, Lovenox, was first approved in 1993. To gain approval as a generic, […]
NEJM Journal Watch — Recent Cardiology Articles- Self-Expanding Supraannular Valve vs. Balloon-Expandable Valve in TAVR for Small Aortic Annulus
- A New TAVR Prosthesis for Aortic Regurgitation Shows Promise
- Aprocitentan, a Newly Approved Drug for Resistant Hypertension
- Preventive PCI of Vulnerable Plaques Linked to Fewer Cardiac Events
- News from the ACC Scientific Session 2024